Preclinical Imaging Market: Market Size & Forecast 2026

Preclinical imaging refers to non-invasive imaging technologies used to visualize and quantify biological processes in animal models during the drug development and biomedical research phases. The global market encompasses a wide range of modalities including magnetic resonance imaging (MRI), positron emission tomography (PET), computed tomography (CT), optical imaging, and ultrasound systems, each serving distinct research applications from oncology to neuroscience. Market valuations from various third-party analyses converge on a 2025 baseline between $3.5 billion and $5.3 billion, with the sector positioned as a critical enabler of modern pharmaceutical research and translational medicine.

• •Market valued at approximately $3.48 billion in 2025, with third-party estimates ranging from $3.53 billion to $5.26 billion depending on scope and methodology
• •Encompasses multiple imaging modalities including MRI, PET, CT, optical imaging, and ultrasound
• •Serves drug discovery companies, academic research institutions, and contract research organizations

The primary growth catalyst is the expansion of global pharmaceutical and biotechnology R&D spending, as novel therapeutics targeting complex diseases require increasingly sophisticated in vivo imaging capabilities. Rising government funding for biomedical research, particularly from public research agencies, has expanded the installed base of imaging equipment at universities and government laboratories. The growing adoption of precision medicine approaches and the need to reduce late-stage drug failures through better translational data have further accelerated investment in high-resolution preclinical imaging platforms.

• •Pharmaceutical R&D expansion and increasing biopharmaceutical pipeline complexity driving demand for advanced imaging tools
• •Public funding from research agencies supporting academic laboratory infrastructure
• •Need to improve drug development success rates through better translational imaging data

The market is segmented by product type, which includes standalone imaging systems, multimodal imaging platforms that combine multiple modalities, and associated software and consumables. Application segments span oncology, cardiology, neurology, immunology, and metabolic disease research, with oncology representing the largest share due to the high volume of cancer drug development programs. North America holds the largest regional share, supported by major pharmaceutical company headquarters, substantial research funding, and established academic medical centers, while Asia-Pacific is emerging as the fastest-growing region due to expanding biopharmaceutical manufacturing and growing research expenditure in countries including China, Japan, and South Korea.

• •Product segments include standalone imaging systems, multimodal platforms, and software/consumables
• •Oncology represents a dominant application area due to high drug development activity
• •North America leads in market share, with Asia-Pacific showing the strongest growth momentum

What are the recent trends and outlook?

The market outlook remains strongly positive through 2030, with consensus forecasts projecting approximately 4.5 percent to 5.9 percent annual growth depending on the source. Key technological trends include the integration of artificial intelligence for image analysis and quantification, the development of higher-field strength MRI systems, and the growing adoption of hybrid imaging modalities that combine complementary technologies. The increasing use of genetically engineered animal models and the expansion of immuno-oncology research are expected to drive sustained demand, while ongoing consolidation among contract research organizations may influence purchasing patterns across the sector.

• •Projected growth rates range from approximately 4.5 percent to 5.9 percent CAGR through 2030
• •AI-assisted image analysis and hybrid multimodal systems represent key technological trends
• •Immuno-oncology research and genetically engineered model adoption expected to sustain demand